Nom du chef de service Jean-Michel MOLINA Mail jean-michel.molina@sls.aphp.fr
Thématique : SIDA recherche clinique
Mots clés : HIV, recherche clinique, essais thérapeutiques
Responsable scientifique : Jean-Michel MOLINA Mail jean-michel.molina@sls.aphp.fr
Intitulé de l’équipe : pas d’équipe labellisée
Encadrement de master ou thèse non
1. SLAMA L, LANOY E, VALANTIN A, BASTARD P, CHERMAK A, BOUTEKATJIRT A, WILLIAM D, BILLAUD E, MOLINA JM, CAPEAU J, COSTAGLIOLA D, ROZENBAUM W. Effect of pioglitazone on HIV-related lipodystrophy : a randomized double –blind placebo-controlled trial. ANRS 113. Antiviral Therapy 2008; 13:67-76
2. MALLAL S, PHILLIPS E, CAROSI G, MOLINA JM, and PREDICT-1 STUDY TEAM. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008 Feb 7;358(6):568-79.
3. LAGRANGE-XÉLOT M, PORCHER R, SARFATI C, DE CASTRO N, CAREL O, MAGNIER JD, DELCEY V, MOLINA JM. Isosporiasis in patients with HIV infection in the highly active antiretroviral therapy era in France. HIV Med. 2008;9(2):126-30.
4. LESPRIT P, PEDRONO G, MOLINA JM, GOUJARD C, GIRARD PM, SARRAZIN N, KATLAMA C, YENI P, MORINEAU P, DELFRAISSY JF, CHENE G, LEVY Y the ANRS 114-Pneumovac Study Group. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS. 2007 Nov 30;21(18):2425-2434.
5. MOLINA JM, COHEN C, KATLAMA C, GRINSZTEJN B, TIMERMAN A, PEDRO RD, VANGENEUGDEN T, MIRALLES D, DE MEYER S, PARYS W, LEFEBVRE E. Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in Treatment-Experienced Patients: 24-Week Results of POWER 3. J Acquir Immune Defic Syndr. 2007; 46(1):24-31.
6. MOLINA JM, JOURNOT V, FURCO A, et al. Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial). Antiviral Therapy 2007; 12: 417-422
7. MOLINA JM, PODSADECKI TJ, JOHNSON MA, WILKIN A, DOMINGO P, MYERS R, HAIRRELL JM, RODE RA, KING MS, HANNA GJ. A Lopinavir/Ritonavir-Based Once-Daily Regimen Results in Better Compliance and Is Non-inferior to a Twice-Daily Regimen Through 96 Weeks. AIDS Res Hum Retroviruses. 2007; 23(12):1505-14
8. CLOTET B, BELLOS N, MOLINA JM, COOPER D, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178
9. MARCHOU B, TANGRE P, CHARREAU I, IZOPET J, GIRARD PM, RAGNAUD JM, MAY T, ABOULKER JP, and MOLINA JM. Intermittent antiretroviral therapy in patients with controlled HIV infection. AIDS 2007, 21:457-66.
10. FLANDRE P, CHAPPEY C, MARCELIN AG, RYAN K, MAA JF, BATES M, SEEKINS D, BERNARD MC, CALVEZ V, AND MOLINA JM. Phenotypic Susceptibility to Didanosine is associated with antiviral activity in treatment-experienced patients with HIV-infection. Journal of Infectious Diseases, 2007;195:392-8.
